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Simple Summary: Circulating tumour cells (CTC) are metastatic seeds that arise from solid tumours
and drive the metastatic spread of malignancy. A better understanding of the biology of CTCs is
critical to enable its clinical application for diagnosis and as a therapeutic target. Currently, CellSearch
is the only method approved by the U.S. Food and Drug Administration (FDA) for CTC enrichment.
However, it isolates only epithelial CTCs and is resource-intensive, which has led to an interest
in developing simpler size-based CTC isolation methods. The MetaCell CTC enrichment kit is a
size-based method which has been previously used for enriching and culturing CTCs in vitro from
several cancer types. Herein, we evaluate the MetaCell platform on its efficacy for retaining colorectal
cancer (CRC) cells spiked into blood and the extent of purity of the enriched CTC fraction, which has
not been described in previous studies utilising MetaCell. We subsequently applied this method to
colorectal cancer patient blood samples and successfully enriched CTCs.
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Abstract: Circulating tumour cells (CTC) from solid tumours are a prerequisite for metastasis.
Isolating CTCs and understanding their biology is essential for developing new clinical tests and
precision oncology. Currently, CellSearch is the only FDA (U.S. Food and Drug Administration)approved method for CTC enrichment but possesses several drawbacks owing to a reliance on
the epithelial cell adhesion molecule (EpCAM) and a resource-intensive nature. Addressing these
shortcomings, we optimised an existing size-based method, MetaCell, to enrich CTCs from blood of
colorectal cancer (CRC) patients. We evaluated the ability of MetaCell to enrich CTCs by spiking blood
with CRC cell lines and assessing the cell recovery rates and WBC depletion via immunostaining
and gene expression. We then applied MetaCell to samples from 17 CRC patients and seven controls.
Recovery rates were >85% in cell lines, with >95% depletion in WBCs. MetaCell yielded CTCs
and CTC clusters in 52.9% and 23.5% of the patients, respectively, without false positives in control
patients. CTCs and cluster detection did not correlate with histopathological parameters. Overall,
we demonstrated that the MetaCell platform enriched CRC cells with high recovery rates and high
purity. Our pilot study also demonstrated the ability of MetaCell to detect CTCs in CRC patients.
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1. Introduction
Ninety percent of all cancer-related deaths, including those in colorectal cancer (CRC),
are attributable to metastasis [1]. There is a strong correlation between diagnosis of colorectal cancer at earlier stages and a better five-year survival rate [2]. The current gold standard
for CRC diagnosis is colonoscopy. Colonoscopy is also the most reliable screening test, but
its role is limited by high cost, invasiveness, and significant miss rates (15–27%) in detecting
small adenomas lesser than 1 cm [3]. Therefore, there is a keen interest in developing a
minimally invasive and sensitive means of early detection and therapeutic monitoring
of CRC which could be facilitated by the emergence of liquid biopsy techniques. Liquid
biopsy involves analysing bodily fluids (usually peripheral venous blood); analytes include circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), and extracellular
vesicles [4].
CTCs are tumour cells derived from solid tumours which travel through the blood
stream or the lymphatic system [5] and are capable of extravasation and further metastatic
dissemination. There has been recent interest in developing CTC-based liquid biopsy technologies for screening, prognostication, and therapeutic monitoring of various cancers, although translation of CTC-based technology for clinical applications remains limited [6–8].
This is due to the very low numbers of CTCs found in the blood for most solid cancers, for example, breast cancer (around 6–7 CTCs/7.5 mL blood) [9] and prostate cancer
(3–5 CTCs/7.5 mL blood) [9], and the even lower numbers are typically found in colorectal
cancer (1–2 CTCs/7.5 mL of blood) [9]. These low numbers pose methodological issues
in developing robust methods for CTC enrichment beyond CellSearch [10] for routine
isolation of CTCs in clinical settings. Hence, there exists a pressing need to develop reliable
methods for CTC enrichment from blood that retain biologically relevant CTC profiles.
In the quest to establish a robust cost-effective technology to routinely enrich CTCs
from the whole blood of cancer patients, more than 100 technologies have so far been
developed [4,11]. These technologies exploit differences in the biological, electrical, and
physical properties of CTCs compared to those of haematopoietic cells, with the aim of
enriching CTC populations for downstream analysis or cell culture [12]. The most widely
used methods involve enrichment based on combinations of cell surface markers [9,13],
each expressed only by either CTCs or leukocytes, allowing easy isolation based on the
combination of markers present on each cell. Marker-based methods usually enrich cells
expressing the epithelial cell adhesion molecule (EpCAM) and exclude CD45-positive
cells, a haematopoietic marker [13,14]. CellSearch is the gold-standard marker-based
method and the sole CTC enrichment technology currently approved by the FDA [15].
Previous work with CellSearch has demonstrated that it can routinely enrich CTCs and
offer prognostication in many solid cancers, such as breast, colon, and prostate cancers.
For example, a study in colorectal cancer patients demonstrated that patients who yielded
at least two CTCs had a shorter overall survival (OS) and progression-free survival (PFS)
of 10.28 and 5.28 months respectively, compared with those of patients who had ≤1
CTC (OS = 24.84 months; PFS = 8.28 months) [16], highlighting the impact of greater CTC
burden, especially after treatment, on the OS and PFS in patients [8,16].
Although there has been much previous research associated with CellSearch and
other marker-based methods, EpCAM-based methods have the drawback of enriching only
epithelial-like CTCs, resulting in considerable loss of CTCs (~20–40%) [17]. Marker-based
methods probably fail to enrich CTCs which have undergone epithelial-to-mesenchymal
transition (EMT), a phenomenon that involves the dynamic switching of the phenotype
from stromal to mesenchymal resulting in several changes, including the loss of EpCAM
expression, which is proposed to aid the survival of CTCs in the bloodstream [1,8,18–20].
High-quality CTC enrichment technologies must enrich CTCs along the entirety of the EMT
spectrum, which cannot be achieved by marker-based methods such as CellSearch, and
reliance on such techniques limits our understanding of CTC biology and metastasis [21].
CTC clusters, often formed by CTCs in intermediate EMT, [22,23] have improved bloodstream survival and metastatic potential when compared to single CTCs, but most current
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marker-based methods, including CellSearch, fail to capture clusters effectively [24–26].
The decreased surface-area-to-volume ratio of cell clusters, in combination with mechanical disruption of clusters in devices with turbulent flow, contributes to the poor efficacy of CellSearch in cluster isolation [22]. Apart from the above-mentioned limitations,
CellSearch is also expensive to implement, prohibiting its adoption in smaller laboratories and widespread clinical use. Microfluidic and membrane-based techniques for CTC
enrichment have demonstrated the ability to capture CTCs along the EMT axis, isolating
a larger spectrum of CTC subpopulations relative to marker-based methods [23]. These
advantages expand the repertoire of CTCs for subsequent analysis and provide greater
success in the capture of CTC clusters, as demonstrated in particular with a modified
ScreenCell method, although further validation with larger sample sizes and a range of
cancer types is needed [24].
The MetaCell CTC kit is a size-based CTC enrichment method which has previously
been used to enrich and culture CTCs in vitro from a multitude of cancer types, including
breast, gynaecological, lung, esophageal, gastric, and urothelial cancers [25–30]. To the
best of our knowledge, there are no reports evaluating WBC depletion and CTC recovery
rates with MetaCell [31], which are important parameters in gauging the performance of
CTC enrichment technologies. Herein, we demonstrate the efficacy of the MetaCell kit for
CTC enrichment by spiking two different colorectal cancer lines (HCT116 and DLD1) into
healthy blood samples and determining recovery rates and WBC depletion rates. We then
further apply this method of CTC enrichment to the peripheral blood samples obtained
from patients with CRC of various AJCC stages. Finally, we describe future directions
for improving the ability of membrane-based methods to capture a wider range of CTC
subpopulations and increasing the repertoire of CTCs for subsequent downstream analysis,
which could further our understanding of CTC biology and the role of CTCs in metastasis.
2. Materials and Methods
2.1. Ethical Approval
Ethical approval was obtained from the University of Otago Human Ethics Committee
(H20/003) to obtain blood from healthy volunteers for use in experimental optimisation
of the MetaCell workflow for two CRC cell lines. Similarly, a Health and Disability Ethics
Committee (HDEC) approval (#14/NTA/33) was obtained in order to collect blood samples
from treatment-naïve CRC patients and control patients with nonmalignant bowel disease
immediately prior to surgery for characterisation and analysis via MetaCell. All participants
provided written informed consent.
2.2. Cell Culture
CRC cell lines (HCT116, DLD1) were obtained from American Type Culture Collection (ATCC), and cell line purity was confirmed by short tandem repeat (STR) profiling.
Once thawed, the cells were cultured in Dulbecco’s Minimal Essential Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS) and maintained at 37 ◦ C and 5% CO2 in
a humidified incubator and confirmed to be free of mycoplasma contamination before use
in experiments.
2.3. Immunostaining to Assess MetaCell Recovery Rates and WBC Depletion Rates
Aliquots of 10, 100, 500, and 10,000 CRC cells (either HCT116 or DLD1) were spiked
into four different 8 mL samples of peripheral venous blood drawn from a healthy volunteer
into a potassium-EDTA Vacutainer tubes (BD Biosciences). Cells were not added to a fifth
blood sample, which served as a negative control. All five blood samples were filtered
through MetaCell, and five MetaCell membranes were detached and placed in different
wells of a six-well plate. Corresponding aliquots of 10, 100, 500, and 10,000 cells were
added directly to four different wells of the six-well plate, serving as an unfiltered control.
After eight hours of incubation, the negative control, unfiltered, and MetaCell-filtered cells
for the different cell numbers were immunostained [32] (Methods S1 and S2; Tables S1–S3)
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with CTC (EpCAM and cytokeratins) and WBC markers (CD45 and CD16), and the images
for the different cell numbers in the unfiltered and MetaCell-filtered groups were visualised
on a Nikon A1+ confocal microscope at 200× magnification. For the unfiltered and the
MetaCell-filtered groups containing 10,000 CRC cells, CRC cells retained on the membrane
which were positive for either or both CTC markers and negative for the WBC markers
were recorded for both groups to qualitatively assess MetaCell’s ability for capturing CRC
cells from spiked blood. In groups containing 10, 100, and 500 cells, cells expressing CTC
markers and negative for WBC markers were manually counted and recorded for both
filtered and unfiltered groups, allowing calculation of recovery rates (Method S2). All of
the above experiments were performed using DLD1 and HCT116 cell lines individually.
The depletion of the WBC population was determined by seeding the peripheral
mononuclear blood cells (PBMCs) extracted from 8 mL of whole blood from a healthy
individual by the density gradient method (Method S2) in a 60 mm culture dish (serving as
unfiltered blood), incubated for eight hours at 37 ◦ C, 5% CO2 , and 95% humidity in RPMI
supplemented with 10% FBS. The cells were immunostained with WBC and CTC markers
(Method S1; Tables S1–S3) and imaged via confocal microscopy (Nikon A1+ inverted
microscope). Similarly, MetaCell-filtered blood without CRC cells (negative control) was
stained with WBC and CTC markers. Images of the stained cells were captured for the
unfiltered and filtered groups, and mean intensities of Alexa Fluor 647, which was tagged
to the WBC markers, was calculated for each of the groups using ImageJ (FIJI). Mean Alexa
Fluor 647 intensity was used to calculate the MetaCell WBC depletion rate (Method S2).
2.4. Gene Expression Analysis for Assessing Recovery and WBC Depletion Rates for MetaCell
RNA was extracted (RNA Mini Easy kit) from the immunostained cells in unfiltered
and the MetaCell-filtered groups. RNA was converted to cDNA using a High-Capacity
cDNA reverse transcriptase kit. 1 ng of cDNA was used for a quantitative polymerase chain
reaction (qPCR) to measure the expression of the two CTC markers, Cytokeratin 20 (KRT20)
and EPCAM. The expression of both CTC markers was normalised with two housekeeping
genes (RPLP0 and PPIA), and the relative fold gene expression was calculated using the
2−∆∆Ct method [33]. The combined gene expression values of the CTC markers in the
unfiltered and the MetaCell-filtered groups for the different cell numbers were used to
calculate recovery rates (Method S3; Table S4).
For evaluating the WBC depletion rate, RNA from the immunostained cells of the
unfiltered blood and negative control (blood without spiked CRC cells) was extracted (RNA
Mini Easy kit) and converted to cDNA (High-Capacity cDNA reverse transcriptase kit).
1 ng of cDNA was used for qPCR to measure the expression of the two WBC markers in both
groups. The expression of both the WBC markers was normalised with two housekeeping
genes (RPLP0 and PPIA), and the relative fold gene expression was calculated using the
2−∆∆Ct method (Method S3). The relative fold gene expression values determined for both
groups were used to determine WBC depletion rates (Method S3).
2.5. Patient Sampling and Blood Processing
8 mL peripheral venous blood samples were collected in potassium-EDTA tubes from
17 CRC patients with various stages of cancer (AJCC stages I-IVB) [34,35], and similarly
from seven noncancer control patients undergoing surgery for nonmalignant colonic disease
(such as Crohn’s disease, ulcerative colitis, and diverticular disease) and were processed
within one hour of collection. The characteristics of the CRC patient population in this
study are summarised in Table 1. An RBC lysis buffer was added to blood samples (1 mL
of blood–5 mL of buffer) and incubated at room temperature for 15 min, after which
samples were filtered through MetaCell. Upon completion of the filtration process, the
membrane was placed in a six-well plate with 4 mL of RPMI medium supplemented with
10% FBS. The plate was incubated for eight hours at 37 ◦ C, 5% CO2 , and 95% humidity.
These samples were subsequently immunostained in the same manner as the spiked blood
samples (Method S1). Based on confocal microscopy, the CTC-positive patients were
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grouped by whether they had either a single CTC or a CTC cluster (CTC +ve) and patients
with a CTC cluster (minimum of two cells attached to each other; cCTC +ve).
Table 1. Patient characteristics. Details of CRC patients used for CTC enrichment by a size-based
method (n = 17).
Characteristics
Age (years)
40–70
71–80
Gender
Male
Female
Ethnicity
New Zealand European
Other European
Clinical Stage (AJCC 8th edition)
Early Stage (stage I and II)
Late Stage (stage III and IV)
Tumour Site
Left sided CRC
Right sided CRC
Metastasis
No distant metastases
Distant metastases present
MMR (IHC)
MMR proficient
MMR deficient
BRAF (IHC)
BRAF V600E −ve
BRAF V600E +ve
ND

Number of Patients (%)
11 (58.8)
6 (35.2)
7 (41.2)
10 (58.8)
15 (88.2)
2 (11.8)
7 (41.2)
10 (58.8)
10 (58.8)
7 (41.2)
11 (64.7)
6 (35.3)
11 (64.7)
6 (35.3)
5 (29.4)
7 (41.2)
5 (29.4)

Abbreviations: IHC—immunohistochemistry, MMR proficient—all four Mismatch Repair (MMR) proteins (MLH1,
PMS2, MSH2, MSH6) present at IHC, MMR deficient—loss of one or more MMR proteins determined by IHC,
BRAF—proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, BRAF V600E +ve—patients
with the mutant BRAF V600E protein determined by IHC, BRAF V600E −ve—patients without the mutant BRAF
V600E protein determined by IHC, ND—BRAF V600E status not determined.

2.6. Statistical Analysis
All statistical analyses were performed on GraphPad Prism 9 version 9.3.1. For
Sections 3.2–3.5, the data were represented as the mean ± SD of three biological replicates,
for both cell lines in the case of Sections 3.2–3.4. After checking the data for a normal
distribution using the Shapiro–Wilk test, p-values were determined by a paired Student’s
t-test. The Wilcoxon test was used for data without a normal distribution (nonparametric).
p-values < 0.05 were considered statistically significant. The pathological characteristics
were expressed as descriptive statistics. The Fischer exact test was used to determine the
association between pathological characteristics and patients identified to have CTCs and
clusters. To check for correlation between CEA levels and the number of single CTCs, the
p-values were determined by Spearman’s rank correlation.
3. Results
3.1. Qualitative Analysis Demonstrates MetaCell’s Ability for Capturing CRC Cells from Blood
Spiked with High CRC Cell Numbers
We initially qualitatively demonstrated the ability of MetaCell to retain CRC cells
from blood spiked with high cell numbers (~10,000 of either HCT116 or DLD CRC cells)
by immunostaining. For both HCT116 and DLD1 experiments, cells retained by MetaCell
were positive for either or both of the CTC markers and negative for both WBC markers
(CD45 and CD16), similar to the unfiltered positive control (Figure 1). In contrast, unspiked
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The immunostaining method in Section 3.1 could not be used to determine recovery
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method
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3.1 couldofnot
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recovratesThe
post-filtering
by manual
counting,
as the number
spiked
cells was
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cells); hence, we used gene expression analysis of two CTC markers (EPCAM and KRT20)
(10,000 cells); hence, we used gene expression analysis of two CTC markers (EPCAM and
to estimate recovery rates [36]. The relative fold gene expression of CTC markers for each
KRT20) to estimate recovery rates [36]. The relative fold gene expression of CTC markers
cell line was 0.89 (unfiltered) and 0.78 (filtered) for HCT116, and 1 for both filtered and
for each cell line was 0.89 (unfiltered) and 0.78 (filtered) for HCT116, and 1 for both filtered
unfiltered DLD1 cells (Figure 2A,B). The relative fold gene expression values between unand unfiltered DLD1 cells (Figure 2A,B). The relative fold gene expression values between
filtered and MetaCell-filtered groups were used to calculate recovery rates and found to
unfiltered and MetaCell-filtered groups were used to calculate recovery rates and found to
be 87.6% (HCT116) and 100% (DLD1 cells).
be 87.6% (HCT116) and 100% (DLD1 cells).
3.3. Quantitative Assessment Demonstrates That MetaCell Recovery Rates Were Not Affected by
Low Cell Numbers
The high recovery rates obtained for the MetaCell kit in HCT116 and DLD1 cells
(Section 3.2) with high cell numbers (~10,000) prompted the investigation of recovery rates
using lower CRC cell numbers (10, 100, 500 cells), which is more reflective of the number
of CTCs likely to be present in the circulation of CRC patients. The CRC cells from the
unfiltered and MetaCell-filtered groups for the different CRC cell numbers were stained
with CTC and WBC markers [37]; cells staining positively for CTC markers and negative
for WBC markers were manually counted. For HCT116 cells spiked in blood at 10, 100, and
500, the MetaCell recovery rates were 85.9%, 86.6%, and 87.6%, respectively (Figure 3A).
Similarly, for DLD1 cells, the MetaCell recovery rates were 90% (10 cells), 88.8% (100 cells),
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and 87.5% (500 cells) (Figure 3B). There were no statistically significant differences in
MetaCell recovery rates across cell numbers for either cell line assessed in this experiment.
Figure 2. Quantitative analysis of CTC markers in unfiltered and MetaCell-filtered CRC cells. (A)
Expression of CTC markers (EPCAM and KRT20) for unfiltered (HCT116_UF) and MetaCell-filtered
HCT116 cells (HCT116_MF). (B) Expression of CTC markers for unfiltered DLD1 cells (DLD1_UF)
and MetaCell-filtered DLD1 cells (DLD1_MF). Error bars represent the mean ± SD of three biological
replicates. p-values determined by paired Student’s t-test; ns p > 0.05.
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To verify the recovery rates of MetaCell obtained for lower cell numbers (Figure
3A,B) by immunostaining, the recovery rates were secondarily determined for HCT116
and DLD1 cells by gene expression analysis of CTC markers (EPCAM and KRT20) in the
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10, 100, and 500 cell MetaCell-filtered (10, 100, and 500 MF) and unfiltered groups (10, 100,
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To confirm the depletion in WBCs for the MetaCell-filtered fraction observed by the
immunostaining method, the average relative fold gene expression values of the WBC
markers were determined by qPCR. Relative fold gene expression values for CD45 in the
two groups were 1.0 (unfiltered) and 0.03 (MetaCell-filtered) (Figure 5C). Similarly, for
CD16, the relative fold gene expression values were 1.01 (unfiltered) and 0.02 (MetaCellfiltered) (Figure 5C). The gene expression values for CD45 and CD16 in the unfiltered
group were significantly greater compared with those in the filtered group (p < 0.0001
and p = 0.03 for CD45 and CD16, respectively). Using these values, WBC depletion in the
MetaCell-filtered fraction was 97% (CD45) and 98% (CD16).
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3.6. Patient Characteristics and CTC Detection
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of not
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in patients with nonmalignant colonic disease (Figure S1). Two of these nine CTC-positive
patients showed presence of both a single CTC and a cluster. All CTCs we detected were
positive for cytokeratins; some also expressed EpCAM, but none expressed EpCAM alone
(Table S5).
We assessed the correlation between CTC detection and demographic factors such as
age and gender or clinicopathological parameters: AJCC stage, tumour site (left or right
colon), or the presence of distant metastasis. We did not observe any significant dependency
on AJCC stage, tumour site, or the presence of distant metastasis on the detection of CTC
+ve and cCTC +ve patients (Table 2).
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Table 2. Association of clinical and pathological variables with patients positive for single CTC and
CTC clusters.
n

% CTC +ve
Patients (n)

% CTC −ve
Patients (n)

40–70

11

54.5 (6)

45.5 (5)

71–85

6

50 (3)

50 (3)

7

71.4 (5)

28.6 (2)

Clinical or
Pathological Variables

p-Value

% cCTC +ve
Patients (n)

% cCTC −ve
Patients (n)

18.2 (2)

81.8 (9)

33.3 (2)

66.7 (4)

42.8 (3)

57.2 (4)

10 (1)

90 (9)

14.3 (1)

85.7 (6)

30 (3)

70 (7)

p-Value

Age (years)
>0.99

0.58

Gender
Male
Female

10

40 (4)

60 (6)

7

71.4 (5)

28.6 (2)

0.33

0.25

Clinical stage
Early stage (I & II)
Late stage (III & IV)

10

40 (4)

60 (6)

0.33

0.60

Tumour site
Left side

10

60 (6)

40 (4)

Right side

7

42.8 (3)

57.2 (4)

11

54.5 (6)

45.5 (5)

0.63

30 (3)

70 (7)

14.3 (1)

85.7 (6)

18.2 (2)

81.8 (9)

33.3 (2)

66.7 (4)

27.2 (3)

72.8 (8)

16.6 (1)

83.4 (5)

0.60

Metastasis
No distant metastases
Distant metastases present

6

50 (3)

50 (3)

11

63.6 (7)

36.4 (4)

>0.99

0.58

MMR (IHC)
MMR proficient
MMR deficient

6

33.3 (2)

66.7 (4)

0.33

>0.99

BRAF V600E (IHC)
BRAF −ve

5

40 (2)

60 (3)

40 (2)

60 (3)

BRAF +ve

7

42.8 (3)

57.2 (4)

14.3 (1)

85.7 (6)

ND

5

80 (4)

20 (1)

20 (1)

80 (4)

>0.99

0.52

Abbreviations: n—total number of patients, CTC +ve—patients positive for single CTC or cluster,
cCTC +ve—patients positive for clusters only, IHC—immunohistochemistry, MMR proficient—all four Mismatch Repair (MMR) proteins (MLH1, PMS2, MSH2, MSH6) present at IHC, MMR deficient—loss of one or more
MMR proteins determined by IHC, BRAF—proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene
homolog B, BRAF V600E +ve—patients with mutant BRAF V600E protein determined by IHC, BRAF V600E
−ve—patients without the mutant BRAF V600E protein determined by IHC, ND—BRAF V600E status not determined. p-value indicates significance according to the Fischer’s exact test for testing the relation between
clinicopathological parameters and CTC detection.

As part of normal pathological review, resected tumours were assessed for the presence
of normal mismatch repair (MMR) proteins by immunohistochemistry (IHC) and described
as MMR proficient (presence of all four MMR proteins: MLH1, PMS2, MSH2, MSH6) or
MMR deficient (absence of one or more MMR proteins). We did not observe a significant
correlation between detection of CTC +ve or cCTC +ve and the presence or absence of
normal MMR proteins in the tumours (Table 2). However, higher percentages of CTC +ve
(63.6%) and cCTC +ve patients (27.2%) were seen in patients with proficient MMR. BRAF
V600E status was similarly assessed in some resected tumour specimens via IHC. Patients
were classified as BRAF V600E positive (presence of mutant protein), BRAF V600E negative
(absence of mutant protein), and ND (patients where the status of the BRAF V600E protein
was not known). A higher proportion of cCTC+ve (40%) patients was observed for the
BRAF V600E-negative group (40%) when compared to that for the BRAF V600E-positive
group (14%), although this correlation did not reach statistical significance (Table 2).
Carcinoembryonic antigen (CEA) levels in the blood are commonly measured for
CRC prognostication. We noted that in CTC-positive patients, CTC counts were higher
with increasing carcinoembryonic antigen (CEA) levels; in patients with CEA levels in the
range of 1–3 µg/L, we found 1–2 CTCs, with higher CTC numbers at CEA levels ≥5 µg/L
(Figure 7, Table S6). A strong correlation (p = 0.008) was seen between the number of single

Cancers 2022, 14, 3446

11 of 17

Cancers 2022, 14, x FOR PEER REVIEW

11 of 17

CTCs and the CEA concentrations (Figure 7), although this trend was lost when considering
both CTC-positive and negative patients (p = 0.645) (Figure S2).
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4. Discussion
In our study, we used an existing membrane-based technology, MetaCell, for enriching CTCs from CRC patients’ blood. While MetaCell has been previously used for enrichment and in vitro culture of CTCs from various cancer types, there is a lack of studies
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4. Discussion
In our study, we used an existing membrane-based technology, MetaCell, for enriching
CTCs from CRC patients’ blood. While MetaCell has been previously used for enrichment
and in vitro culture of CTCs from various cancer types, there is a lack of studies assessing WBC depletion and recovery rates, which are important parameters for gauging the
efficiency of CTC enrichment technologies. Therefore, in this study, we first evaluated
these parameters before applying MetaCell for CTC enrichment from CRC patients’ blood.
Initially, we demonstrated high recovery rates for MetaCell from healthy blood spiked
with high CRC cell numbers (HCT116 and DLD1). We further explored the effect of lower
CRC cell numbers (10, 100, and 500 cells) on recovery rates, as the cell concentrations we
used initially did not accurately mirror CTC concentrations that circulate in a patient’s
blood (1–10 CTCs per mL [38]). We did not observe any difference in recovery rates across
different cell concentrations or cell lines; all groups exhibited good recovery rates of at
least 85%, using both manual counting and gene expression analysis. These recovery rates
are similar to those of CellSearch, estimated to capture around 82% of CTCs, and another
microfluidic technology with a similar recovery rate of 85% [39,40]. It would have been
ideal to evaluate the performance of MetaCell in blood spiked with <10 CRC cells, which
would be more representative of CTC numbers obtained from the blood of CRC patients.
However, since we used serial dilution for obtaining cell fractions, increasing the number
of dilutions and decreasing the volume of spiked cells would increase error and decrease
the likelihood that our spiked cell fraction accurately represents the number of cells we aim
to spike. This could have a significant influence on the accuracy of recovery rates obtained
for MetaCell at these low cell numbers (<10 CRC cells), hence further dilutions were not
undertaken. Additionally, the main reason for performing cell line experiments was to
provide evidence of MetaCell’s ability to isolate CTCs, which we considered adequately
demonstrated with 10 spiked cells to progress to patient samples.
A consistent drawback of current CTC enrichment methods is the high background of
WBCs that are retained in the enriched CTC fraction, which not only provides challenges in
the downstream bulk DNA/RNA processing of CTCs but may also disrupt CTC enrichment
by clogging the pores of the membrane [41]. We demonstrated that MetaCell was able to
deplete >95% of the WBC population via immunostaining and gene expression analysis of
the WBC markers, which was similar to the depletion rates achieved by a spiral microfluidic
device where over 99% of depletion in WBCs was reported [40]. Our gene expression
analysis showed that traces of WBCs remained in the MetaCell-enriched fraction missed
by the immunostaining approach, demonstrating that qPCR methods could be a more
accurate approach for determining WBC depletion achieved by MetaCell.
The results from our optimisation experiments supported the application of this
method for the isolation of CTCs from peripheral blood of 17 CRC patients, presenting
at different stages of malignancy, as well as seven patients with nonmalignant colorectal disease. We detected CTCs in 52.9% of CRC patients using MetaCell, which was in
concordance with another study utilising a similar filter-based device, isolation by size of
tumour cells (ISET), where CTCs were obtained from 52.8% of the CRC patients [42]. The
similar proportion of CRC patients without detectable CTCs suggest that a pore size of
8 µm may not be ideal; indeed, it has been previously demonstrated that CTCs in CRC
are sometimes smaller than 8 µm [43,44]. The loss of smaller CTCs through the pores of
the membrane may explain why nearly half of our cohort did not yield a single CTC. It
would be interesting to apply a sequential filtration technique with membranes of different
pore sizes (<8 µm) and investigate whether this improves the performance of membranebased technologies. Capturing not only smaller CTC populations but also single CTCs
and clusters from the same patient has been demonstrated in another membrane-based
approach for CTC enrichment [24]. Such an approach enables comparative studies on
paired single CTCs and CTC clusters to gain a better understanding on the role of these
CTC subpopulations in CRC metastasis.
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While membrane-based methods such as MetaCell have several advantages, phenotypic characterisation of CTCs enriched by membrane-based methods are usually performed via immunocytochemistry and fluorescence microscopy with only one or two
additional markers [45]. This limited our use of markers and prompted us to choose the
most popular markers used for CTC characterisation, i.e., EpCAM and cytokeratins [46,47].
Furthermore, using these markers allows some comparison of the efficiency of MetaCell to
isolate phenotypically similar cells to that of CellSearch. Although these epithelial markers
may be useful in separating WBCs from candidate CTCs, the isolated cells may not in all
cases be malignant; previous evidence demonstrates that circulating cells with epithelial
markers are present in the blood of patients with nonmalignant colorectal disease, although
we observed no such cells in our study [48]. Our dependence upon epithelial markers additionally meant that we could not verify whether MetaCell was able to detect CTCs along
the EMT continuum with a loss of these markers, although these CTC populations may
be more relevant to metastasis [49]. Further approaches should assess the suitability of a
wider range of CTC markers, including mesenchymal and epithelial markers, to investigate
if the use of mesenchymal markers could improve the efficiency of MetaCell for enriching
CTCs, as this represents a domain in which MetaCell may eclipse the utility of CellSearch.
We also explored the association between the detection of CTCs with several clinicopathological and demographic features. We did not observe any significant correlation
between CTC detection and age, gender, AJCC stage, or distant metastasis. Distinct
metastatic patterns in colorectal cancer patients exist based on primary tumour location,
which prompted us to investigate whether the location of the primary tumour had a bearing
on CTC detection [50,51]. In our cohort we did not observe a significant influence of the
primary tumour location on CTC detection.
As per clinical guidelines, the assessment of MMR proficiency and the BRAF V600E
protein in resected tumours is recommended to inform adjuvant treatment selection [52,53].
Impairments in the DNA mismatch repair (MMR) system are caused by a mutation in any
one of the four genes (MLH1, PMS2, MSH2, and MSH6) that constitute the MMR system.
MMR-deficient (dMMR) tumours are more vulnerable to microsatellite instability (MSI),
observed in 12–17% of sporadic CRCs. In sporadic CRC, MMR deficiency is often accompanied by BRAF V600E mutations occurring due to MLH1 promoter hypermethylation [54].
Although greater CTC burden may occur in tumours with MSI [55], we did not find any
significant correlation between MMR or BRAF V600E status and CTC detection in the
present study.
Carcinoembryonic antigen (CEA) is a serum marker with prognostic value in earlystage CRC and may indicate recurrence after treatment. It has been previously demonstrated that the combination of CTC number and CEA levels could provide a more accurate
prognosis in CRC patients, due to the range of factors normally affecting CEA levels
in vivo [56,57]. We observed no significant correlation between CEA levels and CTC numbers in our entire cohort; however, in the CTC-positive patients only, increasing CEA
levels had a positive correlation with the number of CTCs detected. No clear conclusion
can be drawn on the relationship between serum CEA and CTC numbers based on the
results obtained from our cohort, although our observations warrant further investigation
of this association.
CTC clusters represent an intriguing CTC population, with profound recent interest due to their apparently increased metastatic potential; dissociation of CTC clusters
decreases the rates of metastasis in mice, suggesting a central role for clusters in cancer
spread [58]. We detected CTC clusters in 23% of our cohort, similarly to previous studies
where clusters were detected in over 20% of CRC patients using membrane-based isolation [24,42]. These observations highlight the utility of membrane-based methods for
capturing CTC clusters. We further investigated the correlation between various demographic and histopathological features and CTC cluster isolation, none of which correlated
significantly with cluster detection. As the primary focus of this study was to demonstrate
MetaCell’s ability to enrich CTCs from blood of colorectal cancer patients, we enrolled a

Cancers 2022, 14, 3446

14 of 17

small cohort of patients after diagnosis and prior to any treatment to maximise the chance of
CRC CTC isolation. The enrolment after diagnosis and prior to treatment contributed to the
short follow-up duration in our cohort which limited our investigation of reliability of this
method for early diagnosis and/or monitoring of the disease and prognostic significance.
Our future studies would be directed at establishing a relationship between CTCs enriched
using MetaCell and progression-free survival/overall survival.
5. Conclusions
CTCs have the potential to be developed as a minimally invasive means for early
detection and therapeutic monitoring as they can be detected in the blood of cancer patients.
However, their clinical translation is limited due to very low numbers of CTCs that can
be found in the blood, coupled with a lack of robust methods for isolation. The first
step towards developing these cells as biomarkers is to optimise a method to successfully
enrich these rare cells with high purity. Currently, CellSearch is the only FDA-approved
method, and has the drawback of enriching only for CTCs that express EpCAM. This
shortcoming can be overcome by adopting a size-based approach for CTC enrichment.
Here, we have demonstrated the efficiency of a size-based method (MetaCell) for enriching
CTCs in two CRC cell lines with reasonably high purity. Our results demonstrated the
capability of MetaCell to enrich CTCs from the peripheral blood of CRC patients. It would
also be interesting to investigate the efficiency of filtration devices with membranes having
different pore sizes so that the smaller CTCs which are missed by the current membranebased methods could be captured. Sequential filtration could be the way forward as it
could improve the efficiency of the membrane-based methods and expand the repertoire of
CTCs for further downstream analysis, which could further facilitate exploration the role
of these rare tumour cells in colorectal cancer metastasis.
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